SCHEMBL6163315

SCHEMBL6163315

O=C(c1cc(-c2ccccc2F)nc2ccccc12)N1CCC[C@@H]1CO

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
RAB9A P51151 1/20 0.48
TRPV1 Q8NER1 2/20 0.47
HCRTR1 O43613 5/20 0.47
HCRTR2 O43614 5/20 0.47
KDM4E B2RXH2 4/20 0.46
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PDK2 Q15119 1/20 0.44
TACR3 P29371 1/20 0.44
CCNE2 O96020 1/20 0.44
CDK4 P11802 1/20 0.44
CCND1 P24385 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6165671 1.00 MEN1 (0.49) MEN1POLBKMT2ARAB9ATRPV1
SCHEMBL6164237 1.00 MEN1 (0.49) MEN1POLBKMT2ARAB9ATRPV1
SCHEMBL6165234 0.92 HCRTR1 (0.51) MEN1POLBKMT2ARAB9AHCRTR1
SCHEMBL6164780 0.92 HCRTR1 (0.51) MEN1POLBKMT2ARAB9AHCRTR1
SCHEMBL6166775 0.92 HCRTR1 (0.51) MEN1POLBKMT2ARAB9AHCRTR1
SCHEMBL6165232 0.91 HCRTR1 (0.49) MEN1POLBKMT2ARAB9ATRPV1
SCHEMBL6163609 0.91 HCRTR1 (0.51) MEN1POLBKMT2ARAB9ATRPV1
SCHEMBL6165140 0.91 HCRTR1 (0.49) MEN1POLBKMT2ARAB9ATRPV1
SCHEMBL6165786 0.91 HCRTR1 (0.51) MEN1POLBKMT2ARAB9ATRPV1
SCHEMBL6165793 0.91 HCRTR1 (0.51) MEN1POLBKMT2ARAB9ATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337523-B1 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORP (US) 2005-10-19 EP claimed
US-20040048867-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2004-03-11 US claimed
EP-1337523-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2003-08-27 EP claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US claimed
US-20020161008-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2002-10-31 US claimed
WO-2002014269-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2002-02-21 WO claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161008-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 MEN1 4655/4885POLB 1324/4885KMT2A 968/4885
US-20040048867-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 MEN1 4655/4885POLB 1324/4885KMT2A 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.